0O2.F Sagimet Biosciences Inc.
- Market cap
- EUR 651M
- P/E
- -
- P/B
- 2.66x
- ROE
- -19.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0O2.F undervalued?
Graham numberThe Graham number of Sagimet Biosciences Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sagimet Biosciences Inc. fundamental analysis
No fundamental analysis for Sagimet Biosciences Inc. yet.
Sagimet Biosciences Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also deve…
Full company profileSagimet Biosciences Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sagimet Biosciences Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 2.00M | 0.00 | 0.00 | 0.00 |
| Operating Income | -23.7M | -31.1M | -30.7M | -54.5M | -56.9M | -55.1M |
| EBITDA | - | -31.1M | -30.7M | -54.5M | -56.9M | -55.1M |
| Net Income | -24.4M | -30.5M | -27.9M | -45.6M | -51.0M | -49.2M |
| EPS | -1.10 | -1.38 | -1.22 | -1.42 | -1.57 | -0.80 |
| Balance Sheet | ||||||
| Total Assets | 59.0M | 33.0M | 96.7M | 160M | 116M | 263M |
| Total Liabilities | 217M | 220M | 5.65M | 4.45M | 5.10M | 7.28M |
| Shareholders' Equity | -158M | -187M | 91.1M | 156M | 111M | 256M |
| Cash & Short-term Investments | 56.7M | 158K | 75.1M | 75.8M | 35.0M | 166M |
| Cash Flow | ||||||
| Operating Cash Flow | -21.7M | -24.5M | -23.8M | -42.4M | -45.7M | -39.4M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -21.7M | -24.5M | -23.8M | -42.4M | -45.7M | -39.4M |
| Ratios | ||||||
| ROE | - | - | -30.6% | -29.2% | -45.8% | -19.2% |
| ROA | -41.4% | -92.3% | -28.8% | -28.4% | -43.8% | -18.7% |
| Net Profit Margin | - | - | -1,393.8% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sagimet Biosciences Inc. dividends
Sagimet Biosciences Inc. has not paid dividends in the last 5 fiscal years.
Who owns Sagimet Biosciences Inc.
- Insiders 2.95%
- Institutions 77.89%
- Public & others 19.16%
- Shares outstanding 70.3M
- Free float 56.6M
Sagimet Biosciences Inc. company profile
- Company name
- Sagimet Biosciences Inc.
- Ticker
- 0O2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Fiscal year end
- December
- Address
- 155 Bovet Road, San Mateo, CA, United States, 94402
- Phone
- 650 561 8600
- Website
- sagimet.com
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc. management
8- Mr. David A. HappelCEO, President & Director · born 1962
- Ms. Elizabeth Rozek Esq., J.D.Chief Legal & Administrative Officer · born 1972
- Mr. Urs Greber Ph.D.Co-Founder
- Dr. Lucas Pelkmans Ph.D.Co-Founder
- Mr. Thierry ChaucheCFO & Principal Accounting Officer · born 1976
- Dr. Marie O'Farrell Ph.D.Chief Scientific Officer
- Mr. Robert D'UrsoSenior Vice President of New Products
- Dr. Andreas Grauer M.D.Chief Medical Officer · born 1961